KRAS wild-type status predicts response to cetuximab in metastatic colorectal cancerAlthough cetuximab is approved for the treatment of irinotecan-resistant metastatic colorectal cancer (CRC), response rates are low and markers predictive of response are urgently required. There is some evidence to ...
many tumors containing wild-type RAS still do not respond to these therapies. Therefore, studies have addressed【写姓名地址; 致函; 演说; 演讲; 向…说话】 factors downstream of RAS as possible additional biomarkers predic...
14. Yaeger R, et al. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov. 2024 Jun 3;14(6):982-993. 15. Ryan MB, et al. KRASG12C-...
11. Spira Alexander I, Tu Huakang, Aggarwal Shivani, et al. A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.[J] .Lung Cancer, 2021, 159: 1-9. 12. Borghaei Hossein, Paz-Ares ...
BENNOUNA J,HIRET S,BERTAUT A,et al. Continuation of bevacizumab vs cetuximab plus chemotherapy after first progression in KRAS wild-type metastatic colorectal cancer: the UNICANCER PRODIGE18 randomized clinical trial [J]. JAMA Oncol,2019,5(1):83-90. ...
Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer. Payam Azadeh,Nafiseh Mortazavi,Arezoo Tahmasebi,Farnaz Hosseini Kamal,Kambiz Novin. Journal of Chemotherapy . 2015Cetuximab plus various chemotherapy regimens for patients with KRAS wild-type metastatic...
KRAS野生型的转移性结直肠癌的一线治疗探讨(王志强)KRAS野生型的转移性结直肠癌一线治疗探讨 中山大学肿瘤防治中心内科王志强 概要 病例介绍：KRAS野生型的转移性结直肠癌患者 贝伐珠单抗和西妥昔单抗的临床研究数据 KRAS野生型患者的最佳一线治疗是什么？正在进行的临床研究 存在问题 病例（一）...
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.
Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS exon 2 are resistant to cetuximab treatment. We set out to identify a... HC Hsu,KT Tan,YJ Lu,... - 《Oncotar...
基金 国家自然科学基金资助项目(82073223) 国家重点研发计划项目(2016YFC1302605) 国家重点研发计划项目(2016YFC1302600)。 关键词 西妥昔单抗 化疗 KRAS基因野生型 结直肠癌 肝转移 Cetuximab Chemotherapy K-Ras wild-type Colorectal cancer Liver metastases 分类号 K735.34 [历史地理—世界史] 登录...